Literature DB >> 29943713

Serotype Distribution and Antimicrobial Resistance of Shigella Species in Bangui, Central African Republic, from 2002 to 2013.

Sebastien Breurec1,2,3, Clotaire Rafaï1, Manuella Onambele1, Thierry Frank1, Alain Farra1, Arnaud Legrand4, François-Xavier Weill5.   

Abstract

Shigella is a major cause of severe diarrhea in children less than the age of 5 years in sub-Saharan Africa. The aim of this study was to describe the (sub-)serotype distribution and antimicrobial susceptibility of Shigella serogroups from Centrafrican patients with diarrhea between 2002 and 2013. We collected 443 Shigella isolates in total. The most common serogroups were Shigella flexneri (N = 243, 54.9%), followed by Shigella sonnei (N = 90, 20.3%) and Shigella dysenteriae (N = 72, 16.3%). The high diversity of (sub-)serotypes of S. flexneri and S. dysenteriae may impede the development of an efficient vaccine. Rates of resistance were high for ampicillin, chloramphenicol, tetracycline, and cotrimoxazole but low for many other antimicrobials, confirming recommendations for the use of third-generation cephalosporins (only one organism resistant) and fluoroquinolones (no resistance). However, the detection of one extended-spectrum beta-lactamase-producing Shigella organism highlights the need for continued monitoring of antimicrobial drug susceptibility.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29943713      PMCID: PMC6090317          DOI: 10.4269/ajtmh.17-0917

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 2.  Enteric infections and the vaccines to counter them: future directions.

Authors:  Myron M Levine
Journal:  Vaccine       Date:  2006-03-24       Impact factor: 3.641

3.  Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.

Authors:  Nahid Farzam; Reut Ramon-Saraf; Yonit Banet-Levi; Liat Lerner-Geva; Shai Ashkenazi; Joanna Kubler-Kielb; Evgeny Vinogradov; John B Robbins; Rachel Schneerson
Journal:  Vaccine       Date:  2017-08-07       Impact factor: 3.641

4.  Shift in serotype distribution of Shigella species in China, 2003-2013.

Authors:  S Qiu; X Xu; C Yang; J Wang; B Liang; P Li; H Li; S Yi; H Liu; X Cui; Z Wu; J Xie; L Jia; L Wang; R Hao; H Jin; Y Wang; Y Sun; H Song
Journal:  Clin Microbiol Infect       Date:  2014-11-07       Impact factor: 8.067

5.  Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study.

Authors:  Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine
Journal:  Lancet       Date:  2013-05-14       Impact factor: 79.321

6.  Strategy for cross-protection among Shigella flexneri serotypes.

Authors:  F R Noriega; F M Liao; D R Maneval; S Ren; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology.

Authors:  Lorenz von Seidlein; Deok Ryun Kim; Mohammad Ali; Hyejon Lee; Xuanyi Wang; Vu Dinh Thiem; Do Gia Canh; Wanpen Chaicumpa; Magdarina D Agtini; Anowar Hossain; Zulfiqar A Bhutta; Carl Mason; Ornthipa Sethabutr; Kaisar Talukder; G B Nair; Jacqueline L Deen; Karen Kotloff; John Clemens
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

8.  Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis.

Authors:  Li Liu; Shefali Oza; Daniel Hogan; Jamie Perin; Igor Rudan; Joy E Lawn; Simon Cousens; Colin Mathers; Robert E Black
Journal:  Lancet       Date:  2014-09-30       Impact factor: 79.321

9.  Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010.

Authors:  Yuanli Mao; Enbo Cui; Chunmei Bao; Zhenhong Liu; Suming Chen; Juling Zhang; Huan Wang; Chenglong Zhang; Jing Zou; John D Klena; Baoli Zhu; Fen Qu; Zhiyun Wang
Journal:  Gut Pathog       Date:  2013-08-07       Impact factor: 4.181

Review 10.  Shigella Diversity and Changing Landscape: Insights for the Twenty-First Century.

Authors:  Mark Anderson; Philippe J Sansonetti; Benoit S Marteyn
Journal:  Front Cell Infect Microbiol       Date:  2016-04-19       Impact factor: 5.293

View more
  1 in total

1.  When first line treatment of neonatal infection is not enough: blood culture and resistance patterns in neonates requiring second line antibiotic therapy in Bangui, Central African Republic.

Authors:  Andrea Nebbioso; Oluwakemi F Ogundipe; Ernestina Carla Repetto; Calorine Mekiedje; Hugues Sanke-Waigana; Gilles Ngaya; Brecht Ingelbeen; Julita Gil-Cuesta
Journal:  BMC Pediatr       Date:  2021-12-13       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.